New combo therapy may boost repigmentation in vitiligo patients

NCT ID NCT07152626

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 25 times

Summary

This study tests whether adding narrowband UVB light therapy to the daily pill ritlecitinib works better than the pill alone for treating vitiligo. About 56 adults with non-segmental vitiligo covering 4-60% of their body will take part. The main goal is to see how much facial and body color returns after 52 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP

    RECRUITING

    Paris, Creteil, 94010, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU La Réunion

    RECRUITING

    La Réunion, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, 33000, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHu de Nice, Hôpital Archet

    RECRUITING

    Nice, Alpes-Maritime, 06200, France

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HCL

    RECRUITING

    Lyon, 69000, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.